慢性淋巴细胞白血病中循环微泡的特征及其预后相关性

Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.

作者信息

De Luca Luciana, D'Arena Giovanni, Simeon Vittorio, Trino Stefania, Laurenzana Ilaria, Caivano Antonella, La Rocca Francesco, Villani Oreste, Mansueto Giovanna, Deaglio Silvia, Innocenti Idanna, Laurenti Luca, Molica Stefano, Pietrantuono Giuseppe, De Stradis Angelo, Del Vecchio Luigi, Musto Pellegrino

机构信息

a Laboratory of Preclinical and Translational Research , IRCCS Referral Cancer Center of Basilicata (CROB) , Rionero in Vulture , PZ , Italy.

b Department of Onco-Hematology , IRCCS Referral Cancer Center of Basilicata (CROB) , Rionero in Vulture , PZ , Italy.

出版信息

Leuk Lymphoma. 2017 Jun;58(6):1424-1432. doi: 10.1080/10428194.2016.1243790. Epub 2016 Oct 14.

DOI:10.1080/10428194.2016.1243790

PMID:27739922

Abstract

Microvescicles (MV) are shedding particles released by normal and neoplastic cells, whose levels in biological fluids highlight their potential role as disease biomarkers and therapeutic targets. By analyzing 131 newly diagnosed chronic lymphocytic leukemia (CLL), we found that the absolute number of serum CLL MV was significantly higher than in controls, in particular in advanced stages of disease. In addition, CD19 + and CD37+, B-cell derived MV, significantly correlated with high tumor burden. Absolute MV number cutoff selected by ROC analysis distinguished Rai stage 0 patients with shorter time to treatment (TTT) from those with more stable disease. Likewise, in the entire cohort, two groups of patients with different overall survival (OS) and different TTT were identified. At multivariate analysis, serum MV independently predicted for OS (along with Rai stage) and TTT (along with Rai stage, lymphocytes and CD38). In conclusion, circulating MV represent a new potential prognostic biomarker in CLL.

摘要

微泡（MV）是由正常细胞和肿瘤细胞释放的脱落颗粒，其在生物体液中的水平突出了它们作为疾病生物标志物和治疗靶点的潜在作用。通过分析131例新诊断的慢性淋巴细胞白血病（CLL）患者，我们发现血清CLL微泡的绝对数量显著高于对照组，尤其是在疾病晚期。此外，CD19+和CD37+，B细胞来源的微泡，与高肿瘤负荷显著相关。通过ROC分析选择的微泡绝对数量临界值区分了治疗时间（TTT）较短的Rai 0期患者和疾病更稳定的患者。同样，在整个队列中，确定了两组总生存期（OS）和TTT不同的患者。在多变量分析中，血清微泡独立预测OS（与Rai分期一起）和TTT（与Rai分期、淋巴细胞和CD38一起）。总之，循环微泡代表了CLL中一种新的潜在预后生物标志物。